Kalaris Therapeutics
KLRS
61 hedge funds and large institutions have $566M invested in Kalaris Therapeutics in 2020 Q3 according to their latest regulatory filings, with 61 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.4% more ownership
Funds ownership: 0% → 1.4% (+1.4%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$197M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$69.3M |
| 3 |
AG
Artal Group
Luxembourg
|
+$69M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$35.4M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Morgan Stanley
New York
| $120K | +$130K | +190 | New |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $101K | +$109K | +159 | New |
|
53
Legal & General Group
London,
United Kingdom
| $55K | +$60.1K | +88 | New |
|
|
AIP
54
Ameritas Investment Partners
Lincoln,
Nebraska
| $42K | +$45.1K | +66 | New |
|
55
UBS Group
Zurich,
Switzerland
| $28K | +$30K | +44 | New |
|
56
Bank of America
Charlotte,
North Carolina
| $27K | +$29.4K | +43 | New |
|
57
Bank of Montreal
Toronto,
Ontario, Canada
| $25K | +$24.6K | +36 | New |
|
58
Citigroup
New York
| $24K | +$25.3K | +37 | New |
|
|
CG
59
Cutler Group
San Francisco,
California
| $13K | +$15K | +22 | New |
|
60
Simplex Trading
Chicago,
Illinois
| $3K | +$3.42K | +5 | New |
|
|
TWA
61
TCI Wealth Advisors
Tucson,
Arizona
| – | +$683 | +1 | New |
|
KLRS Hedge Fund Activity: Q3 2020 in Review
61 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2020, worth a combined $566M.
Buyers outnumbered sellers: 61 funds opened new KLRS positions and 0 closed out — a net gain of 61 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $197M.
- 61 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $566M of Kalaris Therapeutics stock for Q3 2020.
- 61 funds opened new Kalaris Therapeutics positions in Q3 2020 and 0 closed out, a net change of +61 holders.
- The largest Kalaris Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $197M added.
Based on aggregated 13F filings for Q3 2020.